Enfusion: TAM Penetration Continues To Progress Well (NYSE:ENFN)

The best photo for all

Investment overview

I wrote about Enfusion (NYSE:ENFN) previously with a buy rating as I thought the business would continue to grow, with potential for acceleration given the visible catalysts available. Notably, valuation multiples should start to


Leave a Comment

Your email address will not be published. Required fields are marked *